Meningococcal B vaccines

The Advisory Committee on Immunization Practices (ACIP) voted to broaden the use of Meningococcal B vaccines, Trumenba and Bexsero, to cover individual clinical decision-making (previously referred to as “permissive use”) for persons aged 16-23 years of age. Consistent with this, the VFC resolution for Meningococcal vaccines was updated to reflect that VFC eligible teens 16 through 18 years of age may be vaccinated.


The complete criteria for administering either of the meningococcal B vaccines is as follows:

- Children aged 16 through 18 years without high risk conditions may be vaccinated; or
- Children aged 10 through 18 years at increased risk for meningococcal disease attributable to serogroup B, including:
  - Children who have persistent complement component deficiencies (including inherited or chronic deficiencies in C3, C5-C9, properdin, factor H, or factor D or taking eculizumab [Soliris®]);
  - Children who have anatomic or functional asplenia, including sickle cell disease; or
  - Children identified to be at increased risk because of a meningococcal disease outbreak attributable to serogroup B.

VFC vaccine can be administered to VFC eligible children who meet any of those qualifications. As a reminder, in order to be VFC-eligible, a child must be under 19 years of age and meet any of the following:

- Uninsured;
- Medicaid eligible;
- American Indian/Alaska Native; or
- Underinsured (FQHCs, RHCs, and deputized LPHAs only).

If you have any questions, please contact your VFC liaison at 800-219-3224.